We are delighted to share that miRoncol presented groundbreaking work at the 2022 American Association for Cancer Research Annual Meeting. Our poster, “Development and validation of a novel circulating cell-free microRNA diagnostic model with high accuracy for multi-cancer early detection,” unveiled a noninvasive, blood-based test that uses serum microRNA expression levels to detect multiple cancers with remarkable accuracy. This innovative 4-miRNA diagnostic model showed high sensitivity for many cancers, including lung, colorectal, and pancreatic, with incredibly promising results for ovarian and sarcoma. This is a monumental step forward in the fight against cancer!
https://aacrjournals.org/cancerres/article/82/12_Supplement/5931/699792/Abstract-5931-Development-and-validation-of-a
From the miRoncol archive: This update is presented in its original historical context. Current platform and product information is available throughout the main website.